[ad_1]
AVITA Medical (NASDAQ:RCEL) on Wednesday stated it anticipated industrial income to be within the vary of US$11.0 million to US$11.3 million for the quarter ended March 31. This vary is beneath the beforehand offered income steering of US$14.8 million to US$15.6 million. The revision in steering is attributable to a slower-than-expected conversion charge of latest accounts for our expanded label of full-thickness pores and skin defects, the corporate added. Moreover, RCEL reaffirmed expectations for full-year 2024 income on the decrease finish of the beforehand offered steering of US$78.5 million to US$84.5 million. Supply: Press Launch
[ad_2]
Source link
